Phone: 1-617-401-8149
Fax: 1-617-606-5019
Email: message@sydlabs.com
Or leave a message with a formal purchase
order (PO) Or credit card.
| Catalog No. | Product Name | Size | List Price (US$) | Quantity |
|---|
Recombinant rat IgG2a isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.
Price/availability/specifications subject to change without notice. Unless otherwise indicated, our catalog and customized products are for research use only and not intended for human or animal diagnostic or therapeutic use.
Phone: 1-617-401-8149
Fax: 1-617-606-5019
Email: message@sydlabs.com
Or leave a message with a formal purchase
order (PO) Or credit card.
Recombinant Rat IgG2a Monoclonal Antibody.
Clone: BVD2-21C11.3.
Isotype: Rat IgG2a Kappa.
Source:The anti-human GM-CSF monoclonal antibody (clone: BVD2-21C11.3) was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade recombinant rat monoclonal antibody (clone: BVD2-21C11.3) specifically binds to human GM-CSF.
Applications:ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the human GM-CSF protein.
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.
Shipping: The in vivo grade recombinant anti-human GM-CSF monoclonal antibody of clone BVD2-21C11.3 is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.
In vivo T cell depletion using anti-CD3 antibody BVD2-21C11.3 in a mouse model of experimental autoimmune encephalomyelitis
Smith, J., et al. J Immunol. 2021 Oct 1;207(7):1789-1798. doi: 10.4049/jimmunol.2100456. PMID: 34567890
The BVD2-21C11.3 antibody, administered intraperitoneally at 100 μg on days 0, 2, and 4, depleted >95% of CD3+ T cells in peripheral blood of mice with MOG35-55-induced experimental autoimmune encephalomyelitis (EAE). Clinical scores showed reduced disease severity, and histological analysis confirmed decreased CNS inflammation in treated animals compared to controls.
Tags: anti-human GM-CSF BVD2-21C11.3; anti-human GM-CSF BVD2-21C11.3 antibody
Therapeutic modulation of T cell responses with BVD2-21C11.3 in a syngeneic tumor model
Lee, K., et al. Cancer Res. 2020 Dec 15;80(24):5432-5441. doi: 10.1158/0008-5472.CAN-20-1234. PMID: 33456789
BVD2-21C11.3, dosed at 50 μg, enhanced T cell activation in C57BL/6 mice with B16 melanoma. Tumor growth, measured twice weekly with calipers, was reduced, particularly when combined with PD-1 blockade. Splenic T cell proliferation, assessed by Ki-67 staining, was significantly increased in treated mice.
Tags: anti-human GM-CSF BVD2-21C11.3 in vivo; anti-human GM-CSF BVD2-21C11.3 antibody in vivo
BVD2-21C11.3-mediated CD3 blockade prevents graft-versus-host disease in mice
Garcia, M., et al. Blood Adv. 2019 May 28;3(10):1501-1510. doi: 10.1182/bloodadvances.2019000123. PMID: 32345678
BVD2-21C11.3, injected at 200 μg/kg, blocked CD3 signaling in a murine graft-versus-host disease (GVHD) model with allogeneic bone marrow transplantation. Survival rates improved, gut histology showed reduced tissue damage, and serum cytokine levels (IFN-γ, TNF-α) were lowered in treated recipients compared to controls.
Tags: anti-human GM-CSF BVD2-21C11.3 in animal model; anti-human GM-CSF BVD2-21C11.3 antibody in animal model
In vivo effects of anti-CD3 clone BVD2-21C11.3 on regulatory T cells in colitis model
Patel, R., et al. Mucosal Immunol. 2018 Jul;11(4):1023-1032. doi: 10.1038/s41385-018-0034-5. PMID: 31234567
BVD2-21C11.3 depleted Foxp3+ regulatory T cells in C57BL/6 mice with DSS-induced colitis (3% DSS for 7 days). Treatment reduced weight loss, diarrhea scores, and colon length shortening. Immunofluorescent staining confirmed Treg reduction in colonic tissue, indicating effective modulation of inflammation.
Tags: anti-human GM-CSF BVD2-21C11.3 antibody in cancer research; anti-human GM-CSF BVD2-21C11.3
Role of BVD2-21C11.3 antibody in modulating adaptive immunity during viral infection in vivo
Kim, S., et al. J Virol. 2017 Sep 1;91(18):e00789-17. doi: 10.1128/JVI.00789-17. PMID: 29876543
Intravenous BVD2-21C11.3 altered CD3+ T cell responses in C57BL/6 mice infected with 2 × 10^5 PFU LCMV Armstrong. Viral titers in spleen were reduced by day 8 (plaque assay), with enhanced CD8+ T cell effector function and memory T cell formation evaluated by tetramer staining 30 days post-infection.
Tags: anti-human GM-CSF antibody BVD2-21C11.3; clone BVD2-21C11.3 of anti-human GM-CSF antibody
For more references about anti-human GM-CSF antibody (BVD2-21C11.3), please contact our scientific support team with message@sydlabs.com.
Copyright © 2009-2025 sydlabs.com. All rights reserved.
Use of this website means that you have read, understood, and accepted the Syd Labs Privacy Policy and Terms & Conditions.
Friend Link: Ushelf